MGI Tech Co Ltd

SSE:688114

MGI Tech Co Ltd, a key player in the genomics industry, emerged from the bustling biotech hub of Shenzhen, China, and swiftly carved a niche for itself with cutting-edge sequencing technology. Founded in 2016 as a subsidiary of BGI Group, MGI has dedicated itself to developing advanced genetic sequencing platforms and related products. The company’s mission is clear: to empower life science research and healthcare by providing innovative tools that make sequencing faster, cheaper, and more accessible. At the core of MGI’s success is their proprietary platform sequencing technology, known as the DNBSEQ™, which has garnered attention for its high throughput and accuracy. This technology is pivotal to their business model, as it significantly reduces the cost of sequencing, giving MGI a competitive edge in the market. MGI's business thrives on a dual revenue stream, primarily from the sale of their state-of-the-art sequencing devices and from providing sequencing services. Their portfolio of sequencing platforms, ranging from benchtop sequencers like the MGISEQ-2000 to large-scale units, caters to a diverse clientele, including research institutions, healthcare providers, and industry giants. The company supports this with a robust after-sales service and supply of consumables required for continuous operation, such as reagents and sequencing kits. By embedding itself deeply into the operational frameworks of its clients, MGI not only boosts its device sales but also ensures a persistent revenue flow from ongoing service and supplies. This business model positions MGI Tech Co Ltd as a formidable force, continually driving advancements in genome technology while expanding its global footprint.